Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Multi-center Study to Evaluate the Safety ,Tolerability and Efficacy of LBL-007 Combined With Toripalimab or LBL-007 Combined With Toripalimab and Axitinib Tablets in the Treatment of Unresectable or Metastatic Melanoma

Next Previous
Trial Profile

A Phase I Multi-center Study to Evaluate the Safety ,Tolerability and Efficacy of LBL-007 Combined With Toripalimab or LBL-007 Combined With Toripalimab and Axitinib Tablets in the Treatment of Unresectable or Metastatic Melanoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary) ; LBL-007 (Primary) ; Toripalimab (Primary)
  • Indications Acral lentiginous melanoma; Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Nanjing Leads Biolabs

Most Recent Events

  • 15 Jan 2025 Planned End Date changed from 20 Jun 2025 to 20 Dec 2025.
  • 15 Jan 2025 Planned primary completion date changed from 10 Mar 2025 to 10 Jul 2025.
  • 19 Sep 2024 Planned End Date changed from 20 Dec 2024 to 20 Jun 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top